

# CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

- a) a guide for reporting for authors of RCTs,
- b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

URL: <http://www.jmir.org/2011/4/e126/>

doi: 10.2196/jmir.1923

PMID: 22209829

\* Required

**Your name \***

First Last

Bonnie Spring

**Primary Affiliation (short), City, Country \***

University of Toronto, Toronto, Canada

Feinberg School of Medicine, Northwestern

**Your e-mail address \***[abc@gmail.com](mailto:abc@gmail.com)

bspring@northwestern.edu

**Title of your manuscript \***

Provide the (draft) title of your manuscript.

Multicomponent mHealth intervention for large, sustained change in multiple diet and activity risk behaviors: Make Better Choices 2 RCT

**Name of your App/Software/Intervention \***

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

MBC2 [Make Better Choices 2]

**Evaluated Version (if any)**

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

"Version: 1.f185c"

## Language(s) \*

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

## URL of your Intervention Website or App \*

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

<https://play.google.com/store/apps/deta>

## URL of an image/screenshot (optional)

<https://play.google.com/store/apps/deta>

## Accessibility \*

Can an enduser access the intervention presently?

- access is free and open
- access only for special usergroups, not open
- access is open to everyone, but requires payment/subscription/in-app purchases
- app/intervention no longer accessible
- Other:

## Primary Medical Indication/Disease/Condition \*

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Multiple behavioral risk factors

## Primary Outcomes measured in trial \*

comma-separated list of primary outcomes reported in the trial

"diet and activity composite improvement"

## Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

healthy change in fruits/vegetables, saturated fat, MVPA, and leisure screen time.

## Recommended "Dose" \*

What do the instructions for users say on how often the app should be used?

- Approximately Daily
- Approximately Weekly
- Approximately Monthly
- Approximately Yearly
- "as needed"
- Other:

### Approx. Percentage of Users (starters) still using the app as recommended after 3 months \*

- unknown / not evaluated
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- Other:

### Overall, was the app/intervention effective? \*

- yes: all primary outcomes were significantly better in intervention group vs control
- partly: SOME primary outcomes were significantly better in intervention group vs control
- no statistically significant difference between control and intervention
- potentially harmful: control was significantly better than intervention in one or more outcomes
- inconclusive: more research is needed
- Other:

## Article Preparation Status/Stage \*

At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet - in early draft status
- not submitted yet - in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- published
- Other:

## Journal \*

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Other:

## Is this a full powered effectiveness trial or a pilot/feasibility trial? \*

- Pilot/feasibility
- Fully powered

## Manuscript tracking number \*

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

- no ms number (yet) / not (yet) submitted to / published in JMIR
- Other: JMIR 10528

## TITLE AND ABSTRACT

### 1a) TITLE: Identification as a randomized trial in the title

#### 1a) Does your paper address CONSORT item 1a? \*

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

- yes
- Other:

#### 1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	essential

## Does your paper address subitem 1a-i? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"mHealth"

## 1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	essential

## Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "Multicomponent"

## 1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes")  
Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	essential

## Does your paper address subitem 1a-iii? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: target population are those with "multiple diet and activity risk behaviors"

## 1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

### 1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	essential

### Does your paper address subitem 1b-i? \*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The Make Better Choices 2 (MBC2) trial tested whether a multicomponent intervention integrating mHealth, modest incentives, and remote coaching could sustainably improve diet and activity."

"Participants were randomly assigned to either of two active interventions targeting MVPA Simultaneously with or Sequentially after other diet and activity targets or a stress and sleep contact control intervention."

### 1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	essential

## Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"They used an app and accelerometer to track targeted behaviors and receive personalized remote coaching."

## 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	essential

## Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were recruited by advertisements to an open-access website, screened, and randomly assigned to either of two active interventions targeting MVPA Simultaneously with or Sequentially after other diet and activity targets or a stress and sleep contact control intervention. They used an app and accelerometer to track targeted behaviors and receive personalized remote coaching from trained paraprofessionals."

## 1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The 9-month RCT enrolled 212 Chicago area adults between 2012-2014 with low fruit and vegetable and high saturated fat intakes, low moderate vigorous physical activity (MVPA) and high sedentary leisure screen time. Participants were recruited by advertisements to an open-access website, screened, and randomly assigned to either of two active interventions targeting MVPA Simultaneously with (N=84) or Sequentially after (N=84) other diet and activity targets or a stress and sleep contact control intervention (N=44). They used an app and accelerometer to track targeted behaviors and receive personalized remote coaching from trained paraprofessionals. Perfect behavioral adherence was incentivized \$5/week for 12 weeks. Diet and activity behaviors were measured at baseline, 3, 6, and 9 months; primary outcome was 9-month diet and activity composite improvement."

"Both Simultaneous and Sequential interventions produced large, sustained improvements exceeding Control ( $p < .001$ ), and bringing all diet and activity behaviors to guideline levels. At 9 months, the interventions increased fruit/vegetables by 6.5 servings/day, 95% CI [6.1, 6.8], increased MVPA by 24.7 min/day, 95% CI [20.0, 29.5], decreased sedentary leisure -170.5 min/day, 95% CI [-183.5,-157.5] and decreased saturated fat intake -3.6%, 95% CI [-4.1,-3.1]). Retention through 9-month follow-up was 82.1%. Self-monitoring decreased from 96.3% of days at baseline to 72.3% at 3 months, 63.5% at 6 months, and 54.6% at 9 months ( $P < .001$ ). Neither attrition nor decline in self-monitoring differed across intervention groups."

## 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	essential

## Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

## INTRODUCTION

### 2a) In INTRODUCTION: Scientific background and explanation of rationale

#### 2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	essential

## Does your paper address subitem 2a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Problem="... much of the population lacking biologic cardiometabolic risk factors is not truly at low risk. Instead, they manifest equally impactful behavioral risk factors that warrant targeting for primordial prevention of disease."

Solution="a scalable, multicomponent intervention that integrates mHealth technology, modest incentives, and remote connected coaching. "

## 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	essential

## Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The average adult reports at least two chronic disease risk behaviors; 25% report three or more; and the magnitude of behavior change needed to bring each risk factor into compliance with public health guidance is typically large.[13-16] Unhealthy diet and activity behaviors are the most prevalent lifestyle risks. Fewer than 15% of U.S. adults eat five or more servings of fruits and vegetables daily; median intake is about half that amount.[17] Only 29% meet dietary guidelines to consume less than 10% calories from saturated fats.[18-20] Half fall short of public health recommendations for moderate-vigorous physical activity[21, 22] (MVPA) and more than 50% exceed 2 hours/day watching television.[21, 23] These four behaviors associate separately with heightened risk of cardiovascular disease and cancers, and link with others that predict premature mortality."

## 2b) In INTRODUCTION: Specific objectives or hypotheses

### Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We hypothesized that community dwelling adults with multiple diet and activity risk behaviors could be activated to achieve and maintain guideline levels of these behaviors by a scalable, multicomponent intervention that integrates mHealth technology, modest incentives, and remote connected coaching."

## METHODS

### 3a) Description of trial design (such as parallel, factorial) including allocation ratio

### Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"... a 3-arm prospective randomized controlled trial which compared two sequences of diet and activity intervention to a contact-control intervention. The active interventions targeted MVPA either simultaneously with (Simultaneous) or sequentially after (Sequential) other diet and activity risk behaviors (fruit/vegetables, sedentary leisure screen time). The control intervention addressed stress and sleep. Eligible participants were stratified by gender and individually randomized to a condition using randomly permuted blocks with an allocation ratio of 2:2:1 (Simultaneous: Sequential: Control). "

### 3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

### Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Bankruptcy of the mobile phone service provider necessitated the return and provision of new mobile phones, creating a budget shortfall that required reducing enrollment from 250 to 212 participants. "

### 3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

### 4a) Eligibility criteria for participants

## Does your paper address CONSORT subitem 4a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Inclusion criteria were willingness to be randomized, age 18-65 years, and met all of the following: <5 servings of fruits and vegetables/day; ≥8% daily calories from saturated fat; <150 minutes/week MVPA; >120 minutes/week of leisure screen time (i.e., television, movies, videogames, recreational internet. These discretionary activities were targeted because they can be decreased without jeopardizing necessary work-related activities). Exclusion criteria were unstable medical condition (i.e. uncontrolled hypertension or diabetes), pregnancy or intent to become pregnant, anorexia, bulimia, or binge eating disorder."

### 4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Implicit: could be trained to use the app

### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 4a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were recruited by advertisements to an open-access website."

### 4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Consent document included as supplementary material

## 4b) Settings and locations where the data were collected

### Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants recorded behavioral data via the smartphone app and accelerometer as they went about their daily activities, so study data was collected in each participant's individual natural life setting.

### 4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 4b-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Primary outcome data were reported via smartphone app and measured by accelerometer.

### 4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

### 5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

#### Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

App was locally custom-designed by grant-funded support staff programmers

### 5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	essential

#### Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

multiple rounds of user testing with feedback

### 5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

App was frozen during the trial except for one update to the food database

### 5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

## 5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Screenshots of the MBC2 app appear in the TOC photo provided, and are also shown in the published design paper, attached as supplementary information

## 5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, [webcitation.org](http://webcitation.org), and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Screenshots are published in the appended design paper.

## 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 5-vii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants accessed the internet through study-provided smartphones via study-contracted telecommunications provider. A version of the app, personalized to their assigned study condition was downloaded from Google Play and then locally installed onto their phone.

## 5-viii) Mode of delivery, features/functionality/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionality/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], "whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 5-viii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Inclusion of intervention components was guided by three principles – effectiveness, scalability, and synergy. Telephone coaching was used because it is more scalable than in-person counseling and has demonstrated effectiveness.[31, 32] Since remote coaching produces smaller behavior changes than in-person treatment but larger magnitude changes are maintained better,[32, 33] we used modest incentives to maximize initial behavior change.[34, 35] A smartphone app and accelerometer were used to provide diet and physical activity feedback synchronously to participants and their coaches, enabling connected, maximally personalized, adaptive coaching."

## 5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Those receiving Simultaneous treatment were asked to gradually modify all 3 target behaviors from the outset of the intervention. Those receiving Sequential treatment were asked to modify only sedentary leisure screen time and fruit/vegetables for the first 6 weeks. Between weeks 7-12, they were asked to maintain goal levels for leisure screen time and fruit/vegetables, while progressively increasing MVPA. Control participants were coached to perform 3 relaxation exercises/day and achieve end goals of  $\geq 7.5$  hours of sleep/day and a 30% reduction in stress over the 12-week intervention."

## 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as “type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered”. It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

“During treatment initiation (weeks 1-12), a trained paraprofessional telephoned each participant weekly for a 10-15 minute coaching session. Coaches delivered a sequence of online didactic lessons specific to each condition[37] and used motivational interviewing to tailor counseling using data from the participant’s app and accelerometer. Call frequency decreased to bi-weekly in weeks 13-24 and monthly in weeks 25-40.”

## 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 5-xi? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

None used

### 5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"After screening, eligible candidates attended an in-person session where they discussed the three treatment options' pros and cons, provided written informed consent, and were loaned a smartphone and accelerometer. They were trained to estimate portion sizes, use the assessment version of a custom-built smartphone app to record behaviors (dietary intake, leisure screen time, stress level, relaxation exercises, and sleep), and wear an accelerometer for a baseline week."

"During treatment initiation (weeks 1-12), a trained paraprofessional telephoned each participant weekly for a 10-15 minute coaching session. Coaches delivered a sequence of online didactic lessons specific to each condition[37] and used motivational interviewing to tailor counseling using data from the participant's app and accelerometer. Call frequency decreased to bi-weekly in weeks 13-24 and monthly in weeks 25-40."



6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed



## Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The primary trial outcome was the composite diet and activity improvement score measured during 1-week assessment periods at 3, 6, and 9 months when participants wore an accelerometer and used the assessment app to self-monitor their behaviors without receiving any feedback. Secondary outcomes were healthy change in fruits/vegetables, saturated fat, MVPA, and leisure screen time.

### 6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

N/A

### 6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

“Treatment receipt was measured by the percent of scheduled coaching calls completed. Self-monitoring adherence was assessed by the proportion of days participant used the app and wore the accelerometer to track behaviors during 1-week assessments at baseline, 3, 6, and 9 months.”

## 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

Your answer

## 6b) Any changes to trial outcomes after the trial commenced, with reasons

## Does your paper address CONSORT subitem 6b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No changes to outcomes after commencement of trial.

## 7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

## 7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The average effect size (mean difference in composite diet and activity improvement Z-score divided by common standard deviation) in our previous MBC1 trial equaled 0.46. Based on our power calculations, we aimed to recruit 50 control subjects and 100 subjects into each of the two intervention groups, assuming a correlation of 0.50 for the composite z scores across time and an attrition rate of 20% at the final time point. We powered the study for an effect size in the range of 0.5 for the first Helmert contrast (H1: Simultaneous + Sequential versus control) and 0.4 for the second Helmert contrast (H2: Simultaneous vs. Sequential). Bankruptcy of the mobile phone service provider necessitated the return and provision of new mobile phones, creating a budget shortfall that required reducing enrollment from 250 to 212 participants: 84 allocated to the Simultaneous intervention; 84 allocated to Sequential; and 44 to Control. However, because the observed correlation of the composite z scores over time was smaller ( $r=0.44$ ) than the predicted 0.50, the study remained sufficiently powered for the posited effect sizes. "

## 7b) When applicable, explanation of any interim analyses and stopping guidelines

### Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable, no interim analyses conducted or stopping guidelines specified.

## 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

### Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The random allocation sequence was computer-generated in R, using randomly permuted blocks.

## 8b) Type of randomisation; details of any restriction (such as blocking and block size)

### Does your paper address CONSORT subitem 8b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Randomly permuted blocks were of size 5 with 2 simultaneous, 2 sequential, and 1 control assignment in each block; these randomly permuted blocks were stratified by gender.

## 9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

## Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants learned their treatment assignment by downloading one of three custom-built, intervention-specific study apps.[36] Each app prompted recording of only those behaviors the intervention targeted (i.e., dietary intake, sedentary leisure, and MVPA for the Simultaneous and Sequential conditions; stress, relaxation exercises, and sleep for Control). "

## 10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

## Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Study statisticians (DH, JS) generated the random allocation sequence. Coaches screened and enrolled participants. Coaches learned the participant's treatment assignment at the same time as participants did (i.e., when participant downloaded the intervention-specific study app). Coaches were blinded to treatment allocation prior to the app download.

## 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

### 11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 11a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Once participants were allocated to treatment, study personnel were not blinded to treatment assignment.

### 11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

" After screening, eligible candidates attended an in-person session where they discussed the three treatment options' pros and cons." This "equipoise induction" prompted participants to think about the advantages and disadvantages of all three intervention conditions equally.

## 11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

### Does your paper address CONSORT subitem 11b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

All 3 conditions involved equal treatment burden, by requiring self-monitoring of the same number of behaviors and receipt of the same number of coaching calls.

## 12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

### Does your paper address CONSORT subitem 12a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Intent-to-treat analyses of primary and secondary endpoints used 3-level linear mixed-effects models that treated daily measurements (level 1) nested within one-week assessment periods (level 2) nested within subjects (level 3). Thus, we analyzed at the daily level and considered the correlation of the daily measurements within weeks and subjects by including random subject intercept and time trends at level 3 (subjects), and a random intercept at level 2 (one-week assessment periods). For comparisons across assessment periods, we treated baseline as the reference, and estimated changes at 3-, 6-, and 9-month follow-up. For comparisons between the intervention groups we used Helmert contrasts, in which the first contrast compared the combined Simultaneous and Sequential groups to Control, and the second contrast compared the Simultaneous to the Sequential group. We also included group by time interactions to assess the degree to which change from baseline varied for either of the Helmert contrasts at each follow-up. "

## 12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 12a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Our modeling approach was to use linear mixed models for longitudinal data. This class of models does not require that subjects are measured at all time points, and therefore can include subjects with missing data across time. All randomized participants were included in analyses of primary and secondary outcomes.

## 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses



## Does your paper address CONSORT subitem 12b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No subgroup analyses were performed. Additional analyses of treatment fidelity and adherence were conducted as follows:

"Three components of treatment implementation were assessed: fidelity, receipt, and adherence. Fidelity was considered present for sessions when the coach delivered all required treatment elements correctly (e.g., encouraging a Control participant to go to bed earlier) and absent if the coach delivered any incorrect treatment element (e.g., encouraging a Control participant to exercise in order to be tired at bedtime). Treatment receipt was measured by the percent of scheduled coaching calls completed. Self-monitoring adherence was assessed by the proportion of days participant used the app and wore the accelerometer to track behaviors during 1-week assessments at baseline, 3, 6, and 9 months. Goal attainment was assessed by the proportion of weeks during treatment initiation when the participant met behavioral goals."

"Baseline characteristics were compared across groups using ANOVA for continuous variables and chi-squared tests for categorical variables. The percentage of coaching calls received and completed in the first versus the second six weeks of treatment was analyzed using repeated measures ANOVA. The percentage of days participants adhered to self-monitoring was measured at baseline, 3-, 6-, and 9-months and analyzed using repeated measures ANOVA. Goal attainment (yes/no), measured every two weeks during treatment initiation, was analyzed using mixed-effects logistic regression with time modeled as either the first or the second 6-weeks of initiation. All models of treatment receipt, adherence, and goal attainment included group by time interactions to assess differences between groups at each time point. "

X26) REB/IRB Approval and Ethical Considerations  
[recommended as subheading under "Methods"] (not a  
CONSORT item)



### X26-i) Comment on ethics committee approval

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

#### Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The Northwestern University institutional review board approved all procedures"

### x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

#### Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"After screening, eligible candidates attended an in-person session where they discussed the three treatment options' pros and cons, provided written informed consent, and were loaned a smartphone and accelerometer"

### X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"During treatment initiation (weeks 1-12), a trained paraprofessional telephoned each participant weekly for a 10-15 minute coaching session. Coaches delivered a sequence of online didactic lessons specific to each condition[37] and used motivational interviewing to tailor counseling using data from the participant's app and accelerometer. Call frequency decreased to bi-weekly in weeks 13-24 and monthly in weeks 25-40."

## RESULTS

### 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

## Does your paper address CONSORT subitem 13a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

See Figure 1

### 13b) For each group, losses and exclusions after randomisation, together with reasons

## Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

See Figure 1

## 13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Loss to follow-up was 17.9% and not differential across treatments (Figure 1). In the composite z analysis, 84.0% of participants provided a composite z score at two or more time points; 68.4% provided 3 or more; and 50.0% provided all four time points.

Receipt of calls declined from 66.0% during the first half of treatment initiation to 57.7% during the second half [ $F(1, 209)=12.05, p<.001$ ], not differing among treatment groups (61.9%; 95% CI, 58.065.7;  $p = .12$ ). Self-monitoring decreased from an average of 96.3% at baseline to 72.3% at 3 months, 63.5% at 6 months, and 54.6% at 9 months ( $F(3, 627)= 95.0, (p<.001)$ , without differences across intervention groups ( $p=.406$ ). Goal attainment was greater for the Active intervention groups (58.8%, 95% CI 52.2%, 65.0%) than Control (33.6%, 95% CI 23.1%, 46.0%) during the first half of treatment initiation, ( $z=3.46, p< 0.001$ ), but Active and Control groups did not differ during the last half of treatment (38.3%, 95% CI 32.6%, 44.2%) ( $z=0.13, p=0.894$ )."

## 14a) Dates defining the periods of recruitment and follow-up

### Does your paper address CONSORT subitem 14a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"the study was conducted in Chicago between July 2012 and July 2014."

## 14a-i) Indicate if critical “secular events” fell into the study period

Indicate if critical “secular events” fell into the study period, e.g., significant changes in Internet resources available or “changes in computer hardware or Internet delivery resources”

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

“Bankruptcy of the mobile phone service provider necessitated the return and provision of new mobile phones, creating a budget shortfall that required reducing enrollment from 250 to 212 participants: 84 allocated to the Simultaneous intervention; 84 allocated to Sequential; and 44 to Control. However, because the observed correlation of the composite z scores over time was smaller ( $r=0.44$ ) than the predicted 0.50, the study remained sufficiently powered for the posited effect sizes.”

## 14b) Why the trial ended or was stopped (early)

### Does your paper address CONSORT subitem 14b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

“Bankruptcy of the mobile phone service provider necessitated the return and provision of new mobile phones, creating a budget shortfall that required reducing enrollment from 250 to 212 participants: 84 allocated to the Simultaneous intervention; 84 allocated to Sequential; and 44 to Control. However, because the observed correlation of the composite z scores over time was smaller ( $r=0.44$ ) than the predicted 0.50, the study remained sufficiently powered for the posited effect sizes.”

## 15) A table showing baseline demographic and clinical characteristics for each group



NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

### Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

See Table 1

### 15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 15-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

See Table 1

## 16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups



## 16-i) Report multiple “denominators” and provide definitions

Report multiple “denominators” and provide definitions: Report N’s (and effect sizes) “across a range of study participation [and use] thresholds” [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants “used” the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define “use” of the intervention.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 16-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

See Figure 1

## 16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only “users”, with the appropriate caveats that this is no longer a randomized sample (see 18-i).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	essential

### Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Intent-to-treat analyses of primary and secondary endpoints used 3-level linear mixed-effects models that treated daily measurements (level 1) nested within one-week assessment periods (level 2) nested within subjects (level 3)."

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

## Does your paper address CONSORT subitem 17a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

See Table 2

### 17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Treatment fidelity averaged 96.8% across the 2-year study; 3 out of 20 coaches required a retraining. Receipt of calls declined from 66.0% during the first half of treatment initiation to 57.7% during the second half [ $F(1, 209)=12.05, p<.001$ ], not differing among treatment groups (61.9%; 95% CI, 58.065.7;  $p = .12$ ). Self-monitoring decreased from an average of 96.3% at baseline to 72.3% at 3 months, 63.5% at 6 months, and 54.6% at 9 months ( $F(3, 627)= 95.0, (p<.001)$ , without differences across intervention groups ( $p=.406$ ). Goal attainment was greater for the Active intervention groups (58.8%, 95% CI 52.2%, 65.0%) than Control (33.6%, 95% CI 23.1%, 46.0%) during the first half of treatment initiation, ( $z=3.46, p< 0.001$ ), but Active and Control groups did not differ during the last half of treatment (38.3%, 95% CI 32.6%, 44.2%) ( $z=0.13, p=0.894$ )."

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended



## Does your paper address CONSORT subitem 17b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

## 18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

### Does your paper address CONSORT subitem 18? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Pre-specified comparisons: "For comparisons across assessment periods, we treated baseline as the reference, and estimated changes at 3-, 6-, and 9-month follow-up. For comparisons between the intervention groups we used Helmert contrasts, in which the first contrast compared the combined Simultaneous and Sequential groups to Control, and the second contrast compared the Simultaneous to the Sequential group. We also included group by time interactions to assess the degree to which change from baseline varied for either of the Helmert contrasts at each follow-up."

"The combined Simultaneous and Sequential interventions produced sustained improvement, as compared to Control, on the composite diet and activity score at 3, 6, and 9 months ( $p < .001$ ) (See Table 2 and Figure 2A). Sequential treatment produced a small, significantly greater composite diet and activity improvement than Simultaneous treatment at 6 months ( $p = .025$ ); however, no differences were evident at 3 and 9 months (see Table 2 and Figure 2B)."

### 18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

## 19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

## Does your paper address CONSORT subitem 19? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No harms or unintended effects noted

## 19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

none noted

## 19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

## DISCUSSION

## 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

## 22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 22-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Primary="These findings support the hypothesis that adults with multiple diet and activity risk behaviors can be activated to make and maintain large improvements in diet and activity behaviors by a scalable, multicomponent intervention that integrates mHealth technology, modest incentives, and remote connected coaching by trained paraprofessionals. Both active MBC2 interventions produced larger sustained improvements in fruit/vegetables, saturated fat, physical activity, and sedentary leisure screen time than those observed in most prior trials, including our MBC1 study, such that all four behaviors surpassed guideline recommended levels at the final study follow-up. Also, unlike the prior MBC1 interventions, both active MBC2 interventions yielded a sustained increase in MVPA documented by accelerometry."

## 22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

## Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Although intervention benefits persisted through 9 months, longer duration follow-up remains needed. "

## 20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses



## 20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 20-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study also had limitations. Three of four behavioral outcomes were assessed exclusively by self-report and could have been subject to demand characteristics. Fruit and vegetable consumption may have been overestimated and time spent in leisure sedentary screen time underestimated. However, although some risk of bias persists, the objective accelerometer derived measure of MVPA also showed large, sustained improvement following the active interventions. Although intervention benefits persisted through 9 months, longer duration follow-up remains needed. A lack of sustained superiority of sequential over simultaneous treatment could have been caused by the fact that goal progression was time dependent, rather than mastery-based. The Sequential intervention added a physical activity goal at week 7, regardless of whether participants had achieved mastery of their fruit/vegetable or sedentary leisure screen time goals. It remains possible that Sequential treatment could have increased MVPA even more if the addition of this new target goal had been delayed until initial behavior targets were reached. "

## 21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

## 21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"MBC2's \$5/week incentive for participants to meet behavioral goals during treatment initiation apparently had the intended effect of motivating participants to make large improvements. Notably, MBC2 participants made somewhat larger diet and activity improvements than those in MBC1, even though the MBC2 incentive was 2/3 smaller. Moreover, no incentive to sustain healthful diet and activity changes was operative in either the MBC1 or MBC2 trial; nevertheless, behavioral improvements were maintained. Hence, these findings contradict the worry that use of incentives followed by their discontinuation inevitably undermines behavioral maintenance. Results accord with a growing body of evidence showing sustained improvements after incentives cease.[34, 35] Potential scalability of modest incentives is suggested by Centers for Medicare and Medicaid reimbursement of contingency contracting for some habit disorders, and by the growing number of individuals and employers that find incentives for healthy lifestyle change cost effective.[57] "

"Including behavior change coaching as a service provided by trained paraprofessionals or artificially intelligent agents could soon make technology-supported behavioral interventions a scalable part of the health care system. "

## 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	essential				

### Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Increasing numbers of worksite wellness programs provide either local or distance coaching and deploy incentives for self-monitoring and behavior change.

"Potential scalability of modest incentives is suggested by Centers for Medicare and Medicaid reimbursement of contingency contracting for some habit disorders, and by the growing number of individuals and employers that find incentives for healthy lifestyle change cost effective.[57] "

## OTHER INFORMATION

### 23) Registration number and name of trial registry

#### Does your paper address CONSORT subitem 23? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Clinical Trial Registration: URL: <http://www.clinicaltrials.gov>. Unique Identifier: NCT01249989 "

### 24) Where the full trial protocol can be accessed, if available

## Does your paper address CONSORT subitem 24? \*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Pellegrini CA, Steglitz J, Johnston W, Warnick J, Adams T, McFadden HG, et al. Design and protocol of a randomized multiple behavior change trial: Make Better Choices 2 (MBC2). Contemp Clin Trials 2015 Mar;41:85-92. PMID:25625810"

## 25) Sources of funding and other support (such as supply of drugs), role of funders

### Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Funding/Support: This study was funded by National Heart, Lung, and Blood grant HL075451 to Dr. Spring and by a career development award (CA154862) to Dr. Siddique. Dr. Stump acknowledges salary support by NIH/NCI training grant T32 CA193193. Research reported in this publication also was supported, in part, by the National Cancer Institute's Robert H. Lurie Comprehensive Cancer Center, Grant Number P30CA60553's and by the National Institutes of Health's National Center for Advancing Translational Sciences, Grant Number UL1TR000150. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.  
"

## X27) Conflicts of Interest (not a CONSORT item)

## X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

	1	2	3	4	5	
subitem not at all important	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	essential

## Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Conflict of Interest Disclosures

Authors report no conflicts of interest."

Funder is NIH; Developers have no commercial interest in the technologies

About the CONSORT EHEALTH checklist 

As a result of using this checklist, did you make changes in your manuscript? \*

- yes, major changes
- yes, minor changes
- no

What were the most important changes you made as a result of using this checklist?

Your answer

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript \*

8 hours

As a result of using this checklist, do you think your manuscript has improved? \*

- yes
- no
- Other:

Would you like to become involved in the CONSORT EHEALTH group?

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

- yes
- no
- Other:

Any other comments or questions on CONSORT EHEALTH

Your answer

**STOP - Save this form as PDF before you click submit** 

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit ! 

Click submit so we have your answers in our database!

**SUBMIT**

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. [Report Abuse](#) - [Terms of Service](#) - [Additional Terms](#)

Google Forms